SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today that it has passed two additional and final third party cellular toxicity tests for its SkinBiotix® technology.
The in vitro tests, for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells), follow on from the recent first stage cytotoxicity tests, as announced on 3 October 2017
The studies were again conducted by Charles River Laboratories, a Contract Research Organisation (CRO), in accordance with the OECD Principles of Good Laboratory Practice.
In the photo-toxicity test, the testers were looking to determine whether the SkinBiotix® technology would become toxic to cells when exposed to UV and visible light. The results showed that SkinBiotix® is non-phototoxic.
The second test, for ocular toxicity, was carried out to determine whether SkinBiotix® is toxic to eye cells. This involved measuring for two important components which are predictive of irritation, corneal opacity (cloudiness) and permeability (ability to let fluids pass through the eye). The SkinBiotix® technology also passed this test.
SkinBioTherapeutics will continue developing the technology towards the three applications in skin care, anti-infection and skin repair.
Dr Catherine O’Neill, CEO of SkinBioTherapeutics plc, commented: “Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy.
“With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets.
“We are continuing formulation development and are confident about starting our human studies in 2018.”
